Compare ODV & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODV | MGTX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | Canada | United States |
| Employees | 102 | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 807.5M | 909.1M |
| IPO Year | N/A | 2018 |
| Metric | ODV | MGTX |
|---|---|---|
| Price | $2.35 | $11.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.57 |
| AVG Volume (30 Days) | ★ 2.8M | 762.2K |
| Earning Date | 08-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | N/A | $141.38 |
| Revenue Next Year | $2.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $2.06 | $6.31 |
| 52 Week High | $4.80 | $11.90 |
| Indicator | ODV | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.91 | 70.94 |
| Support Level | N/A | $7.10 |
| Resistance Level | $3.50 | $11.85 |
| Average True Range (ATR) | 0.14 | 0.61 |
| MACD | 0.00 | 0.26 |
| Stochastic Oscillator | 5.13 | 83.78 |
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company projects include Cariboo Gold Project, Tintic Project, and Exploration.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.